IONS 32.32 (-1.13%)
US4622221004BiotechnologyBiotechnology

Ionis Pharmaceuticals (IONS) Stock Highlights

32.32 | -1.13%
2025-02-22 02:34:55
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and partner Biogen brought Spinraza to market in 2016 as a treatment for a rare neuromuscular disorder, spinal muscular atrophy. Ionis subsequently brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019).

Statistics

Range Today
32 32.87
Volume Today 1.57M
Range 1 Year
30.23 52.34
Volume 1 Year 353.62M
Range 3 Year
29.68 54.44
Volume 3 Year 886.06M
Range 10 Year
19.59 86.58
Volume 10 Year 3.45B

Highlights

Market Capitalization 5.14B (mid)
Floating Shares 157.58M
Current Price 32.32
Price To Earnings -10.75
Price To Revenue 6.88
Price To Book 8.67
Earnings Per Share -3.04
Payout Ratio 0%

Performance

Latest -1.13%
1 Month +2.21%
3 Months -9.26%
6 Months -31.83%
1 Year -29.62%
3 Years +1.54%
5 Years -47.1%
10 Years -51.68%

Benchmarks


Obligatory risk notice

We would like to point out that the contents of this website are for general information purposes only and do not constitute recommendations for the purchase or sale of specific financial instruments, and therefore do not constitute investment advice. In particular, marketstorylabs.com and its creators cannot assess the extent to which information / recommendations made on the pages correspond to your investment objectives, your risk tolerance and your ability to bear losses. Therefore, if you make any investment decisions based on information on the site, you do so solely on your own responsibility and at your own risk. This in turn means that neither marketstorylabs.com nor its creators are liable for any losses incurred as a result of investment decisions based on the information on the marketstorylabs.com website or other media used.